AI
VTGN icon

AdvisorShares Investments’s VistaGen Therapeutics VTGN Stock Holding History

AdvisorShares Investments’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.1K Buy
438,643
+161,533
+58% +$97.4K 0.01% 261
2026
Q1 		$158K Buy
277,110
+26,922
+11% +$16.4K 0.03% 239
2025
Q4 		$166K Buy
250,188
+43,190
+21% +$156K 0.03% 237
2025
Q3 		$735K Buy
206,998
+3,884
+2% +$11.6K 0.12% 92
2025
Q2 		$406K Buy
203,114
+44,000
+28% +$99.9K 0.07% 193
2025
Q1 		$372K Buy
159,114
+59,304
+59% +$168K 0.07% 192
2024
Q4 		$294K Buy
99,810
+32,030
+47% +$90.1K 0.06% 201
2024
Q3 		$204K Buy
67,780
+16,000
+31% +$54.6K 0.04% 219
2024
Q2 		$185K Sell
51,780
-20,291
-28% -$87.9K 0.03% 228
2024
Q1 		$381K Buy
72,071
+17,760
+33% +$85.4K 0.06% 194
2023
Q4 		$279K Buy
+54,311
New +$206K 0.07% 214

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

AdvisorShares Investments's VTGN Position: Q2 2026 in Review

AdvisorShares Investments increased its VistaGen Therapeutics (VTGN) stake by 58% in Q2 2026, buying an estimated $97.4K and bringing the position to 438,643 shares worth $99.1K. The position accounts for 0.01% of the portfolio, ranked #261.

AdvisorShares Investments first reported a position in VTGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $735K in Q3 2025. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • AdvisorShares Investments held 438,643 shares of VistaGen Therapeutics worth $99.1K as of Q2 2026.
  • AdvisorShares Investments bought 161,533 VistaGen Therapeutics shares in Q2 2026, an estimated $97.4K.
  • VistaGen Therapeutics made up 0.01% of AdvisorShares Investments's portfolio in Q2 2026, its #261 holding.
  • AdvisorShares Investments first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • AdvisorShares Investments's VistaGen Therapeutics position peaked at $735K in Q3 2025.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.